[1] WHO. Polio eradication and endgame strategic plan 2013-2018. http://polioeradication.org/who-we-are/strategic-plan-2013-2018. [2020-2-20].http://polioeradication.org/who-we-are/strategic-plan-2013-2018
[2] Greene SA, Ahmed J, Datta SD, Burns CC, Quddus A, Vertefeuille JF, et al. Progress toward polio eradication—worldwide, January 2017—March 2019. MMWR Morb Mortal Wkly Rep 2019;68(20):458 − 62. http://dx.doi.org/10.15585/mmwr.mm6820a3CrossRef
[3] PGEI. Global eradication of wild poliovirus type 2 declared. http://polioeradication.org/news-post/global-eradication-of-wild-poliovirus-type-2-declared. [2015-9-20].http://polioeradication.org/news-post/global-eradication-of-wild-poliovirus-type-2-declared
[4] WHO. Meeting of the strategic advisory group of experts on immunization, October 2015—conclusions and recommendations. Wkly Epidemiol Rec 2015;90(50):681-700. https://www.who.int/wer/2015/wer9050.pdf?ua=1.https://www.who.int/wer/2015/wer9050.pdf?ua=1
[5] GPEI. Polio eradication & endgame midterm review 2015. Geneva, Switzerland: World Health Organization; 2015. https://www.tandfonline.com/doi/ref/10.1080/23762004.2016.1178563. [2020-2-20].https://www.tandfonline.com/doi/ref/10.1080/23762004.2016.1178563
[6] WHO. Two out of three wild poliovirus strains eradicated. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated. [2019-10-24].https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated
[7] WHO. Global eradication of poliomyelitis by the year 2000. In: Forty-first world health assembly. Geneva. https://www.who.int/ihr/polioresolution4128en.pdf. [2020-2-20].https://www.who.int/ihr/polioresolution4128en.pdf
[8] Patel M, Orenstein W. A world free of polio—the final steps. N Engl J Med 2016;374(6):501 − 3. http://dx.doi.org/10.1056/NEJMp1514467CrossRef
[9] Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC. Update on vaccine-derived polioviruses—worldwide, January 2015–May 2016. MMWR Morb Mortal Wkly Rep 2016;65(30):763-9. https://www.jstor.org/stable/24858893.https://www.jstor.org/stable/24858893
[10] PGEI. Circulating vaccine - derived poliovirus. http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/. [2020-2-20].http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/
[11] Mbaeyi C, Wadood ZM, Moran T, Ather F, Stehling-Ariza T, Nikulin J, et al. Strategic response to an outbreak of circulating vaccine - derived poliovirus type 2—Syria, 2017-2018. MMWR Morb Mortal Wkly Rep 2018;67(24):690 − 4. http://dx.doi.org/10.15585/mmwr.mm6724a5CrossRef
[12] Jorba J, Diop OM, Iber J, Henderson E, Zhao K, Sutter RW, et al. Update on vaccine-derived polioviruses—worldwide, January 2017–June 2018. MMWR Morb Mortal Wkly Rep 2018;67(42):1189 − 94. http://dx.doi.org/10.15585/mmwr.mm6742a5CrossRef
[13] WHO. Meeting of the strategic advisory group of experts on immunization, April 2015: conclusions and recommendations. Wkly Epidemiol Rec 2015;90(22): 261-78. https://apps.who.int/iris/bitstream/handle/10665/242365/WER9022_261-278.PDF.https://apps.who.int/iris/bitstream/handle/10665/242365/WER9022_261-278.PDF
[14] Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014;210(Suppl 1):S475 − 84. http://dx.doi.org/10.1093/infdis/jit845CrossRef
[15] Pons-Salort M, Burns CC, Lyons H, Blake IM, Jafari H, Oberste MS, et al. Preventing vaccine-derived poliovirus emergence during the polio endgame. PLoS Pathog 2016;12(7):e1005728. http://dx.doi.org/10.1371/journal.ppat.1005728CrossRef
[16] WHO. Official country reported coverage estimates time series. https://www.who.int/immunization/monitoring_surveillance/data/en/. [2020-2-20].https://www.who.int/immunization/monitoring_surveillance/data/en/
[17] National Primary Health Care Development Agency. 2018 Nigeria polio eradication emergency plan. Abuja: NPHCDA; 2018 Jan. Plot 681/682. http://polioeradication.org/wp-content/uploads/2018/04/Nigeria-National-Polio-Emergency-Plan-2018.pdf.http://polioeradication.org/wp-content/uploads/2018/04/Nigeria-National-Polio-Emergency-Plan-2018.pdf
[18] Mbaey C, Alleman MM, Ehrhardt D, Wiesen E, Burns CC, Liu HM, et al. Update on vaccine - derived poliovirus outbreaks— democratic republic of the Congo and horn of Africa, 2017–2018. MMWR Morb Mortal Wkly Rep 2019;68(9):225 − 30. http://dx.doi.org/10.15585/mmwr.mm6809a2CrossRef
[19] Jafari H, Deshpande JM, Sutter RW, Bahl S, Verma H, Ahmad M, et al. Efficacy of inactivated poliovirus vaccine in India. Science 2014;345(6199):922 − 5. http://dx.doi.org/10.1126/science.1255006CrossRef
[20] John J, Giri S, Karthikeyan AS, Iturriza-Gomara M, Muliyil J, Abraham A, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014;384(9953):1505 − 12. http://dx.doi.org/10.1016/S0140-6736(14)60934-XCrossRef
[21] Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014;210(Suppl 1):S485 − 97. http://dx.doi.org/10.1093/infdis/jit838CrossRef
[22] UNICEF, WHO. Progress and challenges with achieving universal immunization coverage. 2018 WHO/UNICEF estimates of national immunization coverage. Data as of July 2019. https://www.who.int/immunization/monitoring_surveillance/who-immuniz.pdf?ua=1. [2020-2-20].https://www.who.int/immunization/monitoring_surveillance/who-immuniz.pdf?ua=1
[23] PGEI. The introduction of IPV, The OPV switch, and risk mitigation. https://www.who.int/immunhttps://www.who.int/immunization/diseases/ /endgame_objective2/inactivated_polio_vaccine/Update_on_supply_constraints_for_IPV-APRIL2016-final.pdf. [2019-12-10].https://www.who.int/immunhttps://www.who.int/immunization/diseases/ /endgame_objective2/inactivated_polio_vaccine/Update_on_supply_constraints_for_IPV-APRIL2016-final.pdf
[24] UNICEF. Inactivated polio vaccine (IPV): supply update. Copenhagen: UNICEF; 2016 Sep. https://www.unicef.org/supply/index_66260.html. [2020-2-20].https://www.unicef.org/supply/index_66260.html
[25] Gurung S, Harris JB, Eltayeb AO, Hampton LM, Diorditsa S, Avagyan T, et al. Experience with inactivated polio vaccine introduction and the “switch” from trivalent to bivalent oral polio vaccine in the World Health Organization’s Western Pacific region. J Infect Dis 2017;216(S1):S101 − 8. http://dx.doi.org/10.1093/infdis/jiw574CrossRef
[26] He HQ, Wang YM, Deng X, Yue CY, Tang XW, et al. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine: an open-label, Randomized, Controlled Trail in Zhejiang, China. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3367051. [2020-2-20].https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3367051
[27] Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open - label, randomised controlled trial. Lancet 2015;386(10011):2413 − 21. http://dx.doi.org/10.1016/S0140-6736(15)00237-8CrossRef
[28] Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, et al. Immunogenicity of different routine poliovirus vaccination schedules: a randomized, controlled trial in Karachi, Pakistan. J Infect Dis 2018;217(3):443 − 50. http://dx.doi.org/10.1093/infdis/jix577CrossRef
[29] Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta - analysis. J Infect Dis 2014;210(Suppl 1):S439 − 46.
[30] Jorba J, Diop OM, Iber J, Henderson E, Zhao K, Quddus A, et al. Update on vaccine - derived poliovirus outbreaks—worldwide, January 2018 - June 2019. MMWR Morb Mortal Wkly Rep 2019;68(45):1024 − 8. http://dx.doi.org/10.15585/mmwr.mm6845a4CrossRef
[31] Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis 2014;210(S1):S283 − 93. http://dx.doi.org/10.1093/infdis/jiu295CrossRef
[32] Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010;172(11):1213 − 29. http://dx.doi.org/10.1093/aje/kwq320CrossRef
[33] van Damme P, de Coster I, Bandyopadhyay AS, Revets H, Withanage K, de Smedt P, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-Centre phase 1 study. Lancet 2019;394(10193):148 − 58. http://dx.doi.org/10.1016/S0140-6736(19)31279-6CrossRef
[34] WHO. Meeting of the strategic advisory group of experts on immunization, October 2019: conclusions and recommendations. Wkly Epidemiol Rec 2019;94(47):541-60. https://apps.who.int/iris/handle/10665/329963.https://apps.who.int/iris/handle/10665/329963